The ‘Frenzied Growth’ of ADC Drugs is Not the Precision Missile You Imagine
Antibody-Drug Conjugates (ADCs) are considered the “star” drugs in the field of tumor therapy and are currently experiencing explosive growth. To date, 17 ADCs have received regulatory approval, with 13 approved by the U.S. Food and Drug Administration (FDA), and over 300 ADCs are in clinical development. These drugs are often likened to “precision missiles,” … Read more
